Loading
Running a patient's blood through a machine that skims off one type of cell (T cells, or stem cells) and returns the rest; the harvested cells become the raw material for CAR-T or a transplant.
For CAR-T, leukapheresis collects the patient's lymphocytes over 3-4 hours, which are shipped to a manufacturing site; heavy prior chemotherapy or a low lymphocyte count can make the product fail. For autologous transplant, stem cells are mobilised from the marrow into blood with G-CSF (plus plerixafor if needed) and collected the same way, then cryopreserved. Slot availability and vein-to-vein time depend on apheresis capacity, a real bottleneck in cell therapy.
Showing the technology this term belongs to: CAR-T cell therapy.
Shares Vein-to-vein time and manufacturing slots, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy.
Shares Bridging therapy, Lymphodepletion before CAR-T, CAR-T cell therapy.
Shares Apheresis and starting-material collection, Lymphodepletion before CAR-T, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy.
Shares Bridging therapy, Lymphodepletion before CAR-T, CAR-T cell therapy.
Shares Vein-to-vein time and manufacturing slots, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy.
Shares Apheresis and starting-material collection, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy.
Shares Bridging therapy, Autologous stem cell transplant (ASCT), CAR-T cell therapy.
Shares Vein-to-vein time and manufacturing slots, Autologous CAR-T manufacturing, batch by batch, CAR-T cell therapy.